ReviewNature biotechnology2012
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
Review in Nature biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Trial
- From Medical Imaging to Bioprinted Tissues: The Importance of Workflow Optimisation for Improved Cell Function.Expert reviews in molecular medicine · 2025Review
- Predictive modeling for metastasis in oncology: current methods and future directions.Annals of medicine and surgery (2012) · 2025Review
- Lung cancer-associated fibroblasts-mediated collagen deposition drives mediastinal lymph node metastasis in non-small cell lung cancer.Frontiers in oncology · 2025Article
- Gene signatures for cancer research: A 25-year retrospective and future avenues.PLoS computational biology · 2024Article
- Metabolic Reprogramming in Tumor Endothelial Cells.International journal of molecular sciences · 2022Review
- Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.Molecular cancer research : MCR · 2022Article
- Retinoic acid inhibits the angiogenesis of human embryonic stem cell-derived endothelial cells by activating FBP1-mediated gluconeogenesis.Stem cell research & therapy · 2022Article
- Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.NPJ precision oncology · 2022Review
- Hepatocellular carcinoma.Nature reviews. Disease primers · 2021Review
- Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts.Theranostics · 2021Article
- Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.BMC cancer · 2019Article
- Non-alcoholic fatty liver disease--a chronic disease of the 21Journal of biomedical research · 2018Article
- Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.Scientific reports · 2018Article
- Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Human vaccines & immunotherapeutics · 2017Review
- Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis.Nature communications · 2017Article
- Mouse models of metastasis: progress and prospects.Disease models & mechanisms · 2017Review
- Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Oncology letters · 2017Article
- Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.Leukemia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disappointing results from most late-stage clinical trials of cancer therapeutics indicate a need for improved and more-predictive animal tumor models. This insufficiency of models, combined with the advent of a class of drugs that target the tumor microenvironment rather than the tumor cell, presents new challenges for designing and interpreting preclinical efficacy studies. A comparison of the clinical efficacy of anti-angiogenic drugs with their corresponding preclinical studies over the past two decades offers many lessons that can inform and improve the design of experiments in existing mouse models. In addition, technological and logistical advances in mouse models of human cancer over the past five years have the potential to increase the clinical translatability of animal studies.
Indexed as
Identifiers
22781694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.